SG/CALL/ELI LILLY & CO/1000/0.1/19.12.25 | Real-time Bid/Ask 06:44:23 13/05/2024 pm IST | ||
| 6.22 EUR / 6.29 EUR | -3.77% |
|
| Current month | +11.68% | ||
| 1 month | -2.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 6.18 | -4.92% | 0 |
| 10/24/10 | 6.5 | -2.40% | 0 |
| 09/24/09 | 6.66 | -1.62% | 0 |
| 08/24/08 | 6.77 | +10.08% | 0 |
| 07/24/07 | 6.15 | +17.82% | 0 |
Delayed Quote Börse Stuttgart
Last update May 13, 2024 at 12:54 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92Y3 |
| ISIN | DE000SU92Y39 |
| Date issued | 29/02/2024 |
| Strike | 1,000 $ |
| Maturity | 19/12/2025 (585 Days) |
| Parity | 10 : 1 |
| Emission price | 7.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.37 € |
|---|---|
| Lowest since issue | 5.22 € |
| Spread | 0.07 € |
| Spread % | 1.12% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Warrants
- Warrant